Jenny P-y Ting

USPTO Granted Patents = 9 (Patent Applications = 4)

Average Co-Inventor Count = 3.6

ph-index = 2

Forward Citations = 20(Granted Patents)

Company Filing History:

9 out of 1,274

The University of North Carolina at Chapel Hill

where one patent can have more than one assignee

Years Active: 2005-2024

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11918621 - Methods and treatments using toll-like receptor agonists to mitigate hematopoietic myeloid loss, increase gastrointestinal recovery and reduce tumor growth (2024-03-05),

2. 11052149 - Methods and compositions for inducing an immune response (2021-07-06),

3. 9296827 - Methods and compositions for modulating T cell and/or B cell activation (2016-03-29),

4. 8871205 - Methods and compositions for the treatment of immune disorders (2014-10-28),

5. 8501677 - Methods and compositions for modulating T cell and/or B cell activation (2013-08-06),

6. 8067375 - Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor (2011-11-29),

7. 7923545 - Caterpiller gene family (2011-04-12),

8. 7569681 - Caterpiller gene family (2009-08-04),

9. 6844188 - Methods and modified cells for the treatment of cancer (2005-01-18),

Title: Innovations and Contributions of Jenny P-y Ting

Introduction

Jenny P-y Ting is a prominent inventor based in Chapel Hill, North Carolina, contributing significantly to the fields of immunology and gastrointestinal disorders. With a remarkable portfolio of 9 patents, his work focuses on innovative methods and treatments to mitigate the side effects of chemotherapy and enhance recovery in patients.

Latest Patents

Among Jenny’s latest innovations is a patent involving methods and treatments utilizing toll-like receptor agonists. This invention aims to mitigate hematopoietic myeloid loss, promote gastrointestinal recovery, and reduce tumor growth. Specifically, it discloses methods to alleviate side effects from chemotherapy and radiotherapy by administering a therapeutically effective amount of a toll-like receptor 2/6 (TLR 2/6) ligand, including the fibroblast-stimulating lipopeptide 1 (FSL-1). Additionally, it details strategies for treating gastrointestinal disorders and increasing granulocyte colony-stimulating factor (G-CSF) production through FSL-1 compositions. Furthermore, Jenny has developed methods and compositions for inducing an immune response, combining unique polymers and cyclic dinucleotides with antigens and antibodies.

Career Highlights

Jenny P-y Ting has held pivotal positions at notable institutions, including the University of North Carolina at Chapel Hill and Biogen Idec MA Inc. His experience in these organizations has fostered an environment for groundbreaking research and development in therapeutic innovations.

Collaborations

Throughout his career, Jenny has collaborated with esteemed colleagues such as Brian P. O'Connor and So-Young Eun. These partnerships have facilitated a synergistic approach in addressing complex medical challenges through innovative solutions.

Conclusion

The contributions of Jenny P-y Ting to the field of medicine reflect a dedication to improving patient outcomes through innovative treatments. His extensive patent portfolio and collaborative efforts mark him as a key figure in the ongoing advancements within medical research and therapeutics.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com